Published in Cancer Weekly, August 2nd, 2005
Stable disease was observed in a number of patients.
Data on 32 patients were presented in Barcelona, Spain, at the 11th World Conference on Lung Cancer in a poster entitled "Results of a phase II Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Recurrent Non-Small Cell Lung Cancer."
The trial, which was conducted in the United States, was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.